公开(公告)号：US20240197730A1

公开(公告)日：2024-06-20

申请号：US18554158

申请日：2022-04-08

Applicant: Cardiff Oncology, Inc.

Inventor： Maya RIDINGER ,  Mark ERLANDER

IPC: A61K31/502 ,  A61K31/517 ,  A61P35/00

CPC classification number: A61K31/502 ,  A61K31/517 ,  A61P35/00

Abstract: Provided include methods, compositions and kits for treating cancer in a subject. The method can comprise administrating a PARP inhibitor (for example, olaparib) and a PLK1 inhibitor (for example, onvansertib) to the subject in a manner sufficient to inhibit progression of the cancer.

公开(公告)号：US20230183814A1

公开(公告)日：2023-06-15

申请号：US18078615

申请日：2022-12-09

Applicant: Cardiff Oncology, Inc.

Inventor： Peter J.P. Croucher ,  Maya Ridinger ,  Mark Erlander

IPC: C12Q1/6886 ,  A61K31/517 ,  A61K31/7068 ,  A61P35/00

CPC classification number: C12Q1/6886 ,  A61K31/517 ,  A61K31/7068 ,  A61P35/00 ,  C12Q2600/156

Abstract: Disclosed herein include methods, compositions, and kits suitable for use in treating a hematological cancer in a subject. In some embodiments, the method comprises determining the presence or absence of at least one mutation in one or more genes encoding a spliceosome protein in sample nucleic acids from the subject; and administering onvansertib and decitabine to the subject, if the at least one mutation in one or more genes encoding a spliceosome protein is determined to be present in the sample nucleic acids, thereby reducing or inhibiting progression of the hematological cancer in the subject.

公开(公告)号：US20220127682A1

公开(公告)日：2022-04-28

申请号：US17459477

申请日：2021-08-27

Applicant: Massachusetts Institute of Technology ,  Cardiff Oncology, Inc.

Inventor： Michael B. Yaffe ,  Jesse C. Patterson ,  Mark Erlander ,  Peter J.P. Croucher ,  Maya Ridinger

IPC: C12Q1/6886 ,  A61K45/06

Abstract: Certain molecular characteristics of cancer cells or tumors can be indicative of their sensitivity to various combination therapies. The cancer cells or tumors exhibiting such molecular profiles, such as upregulation of genes associated with mitosis or meiosis, can be sensitive to additive and more than additive effects of combination therapies. Methods for identifying, selecting, and/or treating cancer patients whose cancer is amenable to combination therapies including an antiandrogen or androgen antagonist in combination with a Plk inhibitor are disclosed. Administration of the combination of the active agents can reduce cancer cell proliferation or viability and/or tumor burden in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone.

公开(公告)号：US20250017933A1

公开(公告)日：2025-01-16

申请号：US18710027

申请日：2022-11-16

Applicant: Cardiff Oncology, Inc.

Inventor： Maya Ridinger ,  Anju Karki

IPC: A61K31/517 ,  A61K31/496 ,  A61K45/06 ,  A61P35/00 ,  C12Q1/6886

Abstract: Provided include methods, compositions and kits for treating cancer in a subject. The method can comprise administrating an LSD1 inhibitor and a PLK1 inhibitor (for example, onvansertib) to the subject in a manner sufficient to inhibit or reduce progression of the cancer.

公开(公告)号：US20240350500A1

公开(公告)日：2024-10-24

申请号：US18751006

申请日：2024-06-21

Applicant: CARDIFF ONCOLOGY, INC.

Inventor： Maya Ridinger ,  Mark Erlander

IPC: A61K31/519 ,  A61K9/00 ,  A61K31/4745 ,  A61K31/513 ,  A61K39/00 ,  A61K45/06 ,  A61P35/04 ,  C07K16/22

CPC classification number: A61K31/519 ,  A61K9/0053 ,  A61K31/4745 ,  A61K31/513 ,  A61K45/06 ,  A61P35/04 ,  C07K16/22 ,  A61K2039/505 ,  A61K2039/545

Abstract: Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.

公开(公告)号：US20220184086A1

公开(公告)日：2022-06-16

申请号：US17598665

申请日：2020-03-25

Applicant: Cardiff Oncology, Inc.

Inventor： Mark Erlander ,  Thomas H. Adams ,  Maya Ridinger

IPC: A61K31/519 ,  A61K31/58 ,  A61P35/00

Abstract: Provided is a method comprising recommending treatment of a prostate cancer patient with a polo-like kinase-1 (PLK1) inhibitor if the patient has rising prostate specific antigen (PSA) levels.
Also provided is a method comprising measuring prostate specific antigen (PSA) levels in at least two samples from a prostate cancer patient, the samples obtained from the patient at different times; and recommending treatment of the patient with a PLK1 inhibitor if the PSA levels in the samples increase over time, or not recommending treatment of the patient with a PLK1 inhibitor if the PSA levels in the samples do not increase over time. Additionally provided is a method comprising recommending treatment of a PLK1 inhibitor to a patient having a prostate cancer that has an altered androgen receptor that does not require ligand for activation.

公开(公告)号：US20250032495A1

公开(公告)日：2025-01-30

申请号：US18751014

申请日：2024-06-21

Applicant: CARDIFF ONCOLOGY, INC.

Inventor： Maya Ridinger ,  Mark Erlander

IPC: A61K31/519 ,  A61K9/00 ,  A61K31/4745 ,  A61K31/513 ,  A61K35/04 ,  A61K39/00 ,  A61K45/06 ,  C07K16/22

Abstract: Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.

公开(公告)号：US20240352114A1

公开(公告)日：2024-10-24

申请号：US18750887

申请日：2024-06-21

Applicant: CARDIFF ONCOLOGY, INC.

Inventor： Maya Ridinger ,  Mark Erlander

IPC: C07K16/22 ,  A61K31/519 ,  A61K45/06 ,  A61P35/04 ,  A61K39/00

CPC classification number: C07K16/22 ,  A61K31/519 ,  A61K45/06 ,  A61P35/04 ,  A61K2039/505

Abstract: Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.

公开(公告)号：US20230167505A1

公开(公告)日：2023-06-01

申请号：US17792069

申请日：2021-01-13

Applicant: Cardiff Oncology, Inc.

Inventor： Errin SAMUELSZ ,  Mark ERLANDER ,  Maya RIDINGER

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/156

Abstract: Provided herein includes a method comprising analyzing circulating tumor DNA (ctDNA), for example ctDNA in plasma, from a patient with leukemia, to predict and/or determine clinical response. The leukemia can be, for example, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or chronic melomonocytic leukemia (CMML).

公开(公告)号：US20240352115A1

公开(公告)日：2024-10-24

申请号：US18750908

申请日：2024-06-21

Applicant: CARDIFF ONCOLOGY, INC.

Inventor： Maya Ridinger ,  Mark Erlander

IPC: C07K16/22 ,  A61K31/519 ,  A61K39/00 ,  A61K45/06 ,  A61P35/04

CPC classification number: C07K16/22 ,  A61K31/519 ,  A61K45/06 ,  A61P35/04 ,  A61K2039/505

Abstract: Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.